Please login to the form below

Not currently logged in
Email:
Password:

hepatitis

This page shows the latest hepatitis news and features for those working in and with pharma, biotech and healthcare.

Gilead’s Biktarvy gets European approval, setting up battle with GSK

Gilead’s Biktarvy gets European approval, setting up battle with GSK

Gilead is relying on its HIV franchise to maintain its growth, as its once-flagship hepatitis C franchise continues to see sales decline, dropping by 60% to $1bn earlier this year.

Latest news

More from news
Approximately 120 fully matching, plus 365 partially matching documents found.

Latest Intelligence

  • The NHS and ABPI at 70: inching closer to the triple win The NHS and ABPI at 70: inching closer to the triple win

    Meanwhile, the pharma industry is hitting new heights in drug innovation, including cures for diseases such as hepatitis C, haemophilia and huge progress in cancer and cell and gene therapy - but

  • Uncertainty, austerity and Brexit Uncertainty, austerity and Brexit

    on hepatitis C treatments and the recent introduction of the Budget Impact Test.

  • No incentive for a cure No incentive for a cure

    Hepatitis C virus treatments like Maviret from AbbVie, which cures people with hard-to-treat genotype 3 after an 8. ... This is the route the NHS in the UK has taken with innovative hepatitis C treatments; it will only pay for the medication if a patient

  • IQVIA: The High IQ Approach of Human Data Science IQVIA: The High IQ Approach of Human Data Science

    Therapeutic advances during that same period have been remarkable; who would have thought we’d find a cure for hepatitis C, or see immunotherapy transform outcomes in cancer care?

  • IQVIA: The High IQ Approach of Human Data Science IQVIA: The High IQ Approach of Human Data Science

    Therapeutic advances during that same period have been remarkable; who would have thought we’d find a cure for hepatitis C, or see immunotherapy transform outcomes in cancer care?

More from intelligence
Approximately 3 fully matching, plus 44 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics